How to buy Genfit stock | $3.6

Genfit SA is a biotechnology business based in the US. Genfit shares (GNFT) are listed on the NASDAQ and all prices are listed in US Dollars. Genfit employs 122 staff and has a trailing 12-month revenue of around 0.00.

Genfit stock price (NASDAQ: GNFT)

Use our graph to track the performance of GNFT stocks over time.

Genfit shares at a glance

• Key figures

Information last updated 2021-10-18.

Latest market close	$3.60
52-week range	$3.50 - $6.15
50-day moving average	$3.83
200-day moving average	$3.98
Wall St. target price	N/A
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.11

Buy Genfit shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Genfit stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Genfit price performance over time

Historical closes compared with the close of $3.6 from 2021-10-22

1 week (2021-10-15)	-2.17%
1 month (2021-09-24)	-6.25%
3 months (2021-07-23)	-5.26%
6 months (2021-04-23)	-15.09%

1 year (2020-10-23)	-19.46%
2 years (2019-10-23)	-75.17%
3 years (2018-10-20)	N/A
5 years (2016-10-20)	N/A

Genfit financials

Revenue TTM	$5.3 million
Gross profit TTM	$7.8 million
Return on assets TTM	-17.88%
Return on equity TTM	-122.45%
Profit margin	0%
Book value	$0.71
Market capitalisation	$172.2 million

TTM: trailing 12 months

Shorting Genfit shares

There are currently 8,895 Genfit shares held short by investors – that's known as Genfit's "short interest". This figure is 4.4% down from 9,307 last month.

There are a few different ways that this level of interest in shorting Genfit shares can be evaluated.

Genfit's "short interest ratio" (SIR)

Genfit's "short interest ratio" (SIR) is the quantity of Genfit shares currently shorted divided by the average quantity of Genfit shares traded daily (recently around 8552.8846153846). Genfit's SIR currently stands at 1.04. In other words for every 100,000 Genfit shares traded daily on the market, roughly 1040 shares are currently held short.

However Genfit's short interest can also be evaluated against the total number of Genfit shares, or, against the total number of tradable Genfit shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Genfit's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Genfit shares in existence, roughly 0 shares are currently held short) or 0.0002% of the tradable shares (for every 100,000 tradable Genfit shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Genfit.

Find out more about how you can short Genfit stock.

Genfit share dividends

We're not expecting Genfit to pay a dividend over the next 12 months.

Genfit share price volatility

Over the last 12 months, Genfit's shares have ranged in value from as little as $3.5 up to $6.15. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genfit's is 1.1576. This would suggest that Genfit's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Genfit overview

Genfit S. A. , a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Genfit S.

Frequently asked questions

What percentage of Genfit is owned by institutions?
Currently 1.392% of Genfit shares are held by institutions. How many people work for Genfit?
Latest data suggests 122 work at Genfit. When does the fiscal year end for Genfit?
Genfit's fiscal year ends in December. Where is Genfit based?
Genfit's address is: Parc EurasantE, Loos, France, 59120 What is Genfit's ISIN number?
Genfit's international securities identification number is: US3722791098 What is Genfit's CUSIP number?
Genfit's Committee on Uniform Securities Identification Procedures number is: 372279109